Piramal Pharma, 543635, PPLPHARMA Share Price, Rating, Research, Analysis, Fundamental & Historical Data

Stock Summary

Market Cap(Crs)
Stock P:E
Face Value

36,557.50
806.47
10

Enterprise Value(Crs)
Dividend Yield
Price:Book Value

40,802.58
0.04%
4.62

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

10 Years
5 Years
3 Years

-
-
7.60

EBITDA CAGR (%)

10 Years
5 Years
3 Years

-
-
4.27

PAT CAGR (%)

10 Years
5 Years
3 Years

-
-
-63.81

P:E (Median)

8 Years
5 Years
3 Years

P:BV (Average)

8 Years
5 Years
3 Years

EV:EBITDA (Average)

8 Years
5 Years
3 Years

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone

Description Sep 24 Sep 23 Var% Jun 24 Jun 23 Var% Mar 24 Mar 23 Var% Dec 23 Dec 22 Var%
Net Sales 1,284.39 994.24 29.18% 1,063.20 846.43 25.61% 1,525.30 1,054.58 44.64% 1,024.14 813.29 25.93%
Expenses 1,031.50 908.08 13.59% 911.57 829.84 9.85% 1,135.66 965.03 17.68% 898.61 786.02 14.32%
EBITDA 252.89 86.16 193.51% 151.63 16.59 813.98% 389.64 89.55 335.11% 125.53 27.27 360.32%
EBIDTM 19.69% 8.67% 14.26% 1.96% 25.55% 8.49% 12.26% 3.35%
Other Income 106.38 89.08 19.42% 36.76 26.68 37.78% 53.19 62.88 -15.41% 33.11 53.88 -38.55%
Interest 29.95 28.22 6.13% 24.88 33.80 -26.39% 27.66 33.78 -18.12% 17.42 33.22 -47.56%
Depreciation 53.61 50.83 5.47% 51.85 50.37 2.94% 52.50 53.01 -0.96% 51.56 47.19 9.26%
PBT 275.71 96.19 186.63% 111.66 -40.90 - 362.67 65.64 452.51% 89.66 0.74 12,016.22%
Tax 65.65 19.03 244.98% 26.39 -7.54 - 89.59 23.94 274.23% 15.32 3.16 384.81%
PAT 210.06 77.16 172.24% 85.27 -33.36 - 273.08 41.70 554.87% 74.34 -2.42 -
PATM 16.35% 7.76% 8.02% -3.94% 17.90% 3.95% 7.26% -0.30%
EPS 1.58 0.58 172.41% 0.64 -0.25 - 2.06 0.31 564.52% 0.56 -0.02 -

Description Sep 24 Sep 23 Var% Jun 24 Jun 23 Var% Mar 24 Mar 23 Var% Dec 23 Dec 22 Var%
Net Sales 2,241.75 1,911.38 17.28% 1,951.14 1,748.85 11.57% 2,552.36 2,163.58 17.97% 1,958.57 1,715.97 14.14%
Expenses 1,900.14 1,645.74 15.46% 1,746.65 1,616.53 8.05% 2,022.43 1,812.31 11.59% 1,690.20 1,628.64 3.78%
EBITDA 341.61 265.64 28.60% 204.49 132.32 54.54% 529.93 351.27 50.86% 268.37 87.33 207.31%
EBIDTM 15.24% 13.90% 10.48% 7.57% 20.76% 16.24% 13.70% 5.09%
Other Income 61.11 49.19 24.23% 19.54 38.31 -49.00% 26.38 24.50 7.67% 61.51 82.54 -25.48%
Interest 107.64 109.87 -2.03% 106.96 118.52 -9.75% 114.22 104.25 9.56% 105.88 94.65 11.86%
Depreciation 192.22 184.51 4.18% 184.55 173.61 6.30% 196.13 184.41 6.36% 186.32 164.43 13.31%
PBT 102.86 20.45 402.98% -67.48 -121.50 - 215.44 87.11 147.32% 5.41 -89.21 -
Tax 97.53 34.54 182.37% 43.56 -8.53 - 126.21 44.78 181.84% 9.25 16.54 -44.07%
PAT 5.33 -14.09 - -111.04 -112.97 - 89.23 42.33 110.80% -3.84 -105.75 -
PATM 0.24% -0.74% -5.69% -6.46% 3.50% 1.96% -0.20% -6.16%
EPS 0.17 0.04 325.00% -0.67 -0.81 - 0.77 0.41 87.80% 0.08 -0.74 -

Annual Results

Standalone Figures in Rs. Crores /

Consolidated

Description TTM Mar 24 Mar 23 Mar 22 Mar 21
Net Sales 4,897.03 4,390.11 3,443.22 3,340.42 2,938.81 Net Sales Growth 32.05% 27.50% 3.08% 13.67% Cost Of Goods Sold 2,186.02 2,108.84 1,768.48 1,561.51 1,227.77 Gross Profit 2,711.01 2,281.27 1,674.74 1,778.91 1,711.04 GP Margin 55.36% 51.96% 48.64% 53.25% 58.22% Total Expenditure 3,977.34 3,790.71 3,345.69 2,865.14 2,319.88 Power & Fuel Cost - 112.89 107.94 83.83 68.08 % Of Sales - 2.57% 3.13% 2.51% 2.32% Employee Cost - 613.93 548.50 448.03 395.15 % Of Sales - 13.98% 15.93% 13.41% 13.45% Manufacturing Exp. - 317.98 318.40 283.52 246.85 % Of Sales - 7.24% 9.25% 8.49% 8.40% General & Admin Exp. - 341.84 310.59 261.25 209.20 % Of Sales - 7.79% 9.02% 7.82% 7.12% Selling & Distn. Exp. - 212.89 230.60 182.88 135.62 % Of Sales - 4.85% 6.70% 5.47% 4.61% Miscellaneous Exp. - 82.34 61.18 44.12 37.21 % Of Sales - 1.88% 1.78% 1.32% 1.27% EBITDA 919.69 599.40 97.53 475.28 618.93 EBITDA Margin 18.78% 13.65% 2.83% 14.23% 21.06% Other Income 229.44 220.58 341.07 224.79 197.97 Interest 99.91 107.10 115.87 57.29 4.71 Depreciation 209.52 205.26 192.08 165.37 143.64 PBT 839.70 507.62 130.65 477.41 668.55 Tax 196.95 116.40 54.19 94.79 115.28 Tax Rate 23.45% 22.93% 43.81% 20.50% 16.79% PAT 642.75 391.22 69.50 367.54 571.50 PAT before Minority Interest 642.75 391.22 69.50 367.54 571.50 Minority Interest 0.00 0.00 0.00 0.00 0.00 PAT Margin 13.13% 8.91% 2.02% 11.00% 19.45% PAT Growth 673.65% 462.91% -81.09% -35.69% EPS 4.85 2.95 0.52 2.77 4.31

Description TTM Mar 24 Mar 23 Mar 22 Mar 21
Net Sales 8,703.82 8,171.16 7,081.55 6,559.10 6,314.90 Net Sales Growth 15.44% 15.39% 7.97% 3.87% Cost Of Goods Sold 3,160.38 2,954.00 2,703.30 2,451.26 2,059.11 Gross Profit 5,543.44 5,217.16 4,378.25 4,107.84 4,255.79 GP Margin 63.69% 63.85% 61.83% 62.63% 67.39% Total Expenditure 7,359.42 7,000.65 6,453.31 5,609.44 4,886.94 Power & Fuel Cost - 241.59 207.81 163.56 136.70 % Of Sales - 2.96% 2.93% 2.49% 2.16% Employee Cost - 2,029.50 1,896.35 1,588.83 1,467.74 % Of Sales - 24.84% 26.78% 24.22% 23.24% Manufacturing Exp. - 731.64 674.10 589.03 544.09 % Of Sales - 8.95% 9.52% 8.98% 8.62% General & Admin Exp. - 542.00 472.78 428.49 367.25 % Of Sales - 6.63% 6.68% 6.53% 5.82% Selling & Distn. Exp. - 359.75 372.59 317.81 247.91 % Of Sales - 4.40% 5.26% 4.85% 3.93% Miscellaneous Exp. - 142.17 126.38 70.46 64.14 % Of Sales - 1.74% 1.78% 1.07% 1.02% EBITDA 1,344.40 1,170.51 628.24 949.66 1,427.96 EBITDA Margin 15.45% 14.32% 8.87% 14.48% 22.61% Other Income 168.54 201.14 225.11 275.80 164.11 Interest 434.70 448.49 344.18 198.25 163.45 Depreciation 759.22 740.57 676.69 586.18 545.04 PBT 256.23 182.59 -167.52 441.03 883.58 Tax 276.55 161.47 66.31 109.02 114.02 Tax Rate 107.93% 134.78% -38.00% 25.59% 12.64% PAT -20.32 17.82 -186.46 375.96 835.03 PAT before Minority Interest -20.32 17.82 -186.46 375.96 835.03 Minority Interest 0.00 0.00 0.00 0.00 0.00 PAT Margin -0.23% 0.22% -2.63% 5.73% 13.22% PAT Growth 0.00% - - -54.98% EPS -0.15 0.13 -1.41 2.84 6.30

Results Balance Sheet

Standalone Figures in Rs. Crores /

Consolidated

Description Mar 24 Mar 23 Mar 22 Mar 21
Shareholder's Funds 6,712.07 5,261.79 5,123.12 4,100.62 Share Capital 1,322.95 1,193.32 1,185.91 994.60 Total Reserves 5,361.65 4,068.47 3,937.21 3,105.92 Non-Current Liabilities 859.80 1,083.17 800.72 184.38 Secured Loans 363.94 592.34 477.12 0.00 Unsecured Loans 0.00 0.00 0.00 0.00 Long Term Provisions 281.04 274.43 143.85 6.59 Current Liabilities 2,307.35 1,951.29 1,655.39 1,566.96 Trade Payables 1,107.71 761.67 646.80 584.12 Other Current Liabilities 503.64 430.07 488.22 681.78 Short Term Borrowings 531.64 720.34 390.21 165.20 Short Term Provisions 164.36 39.21 130.16 135.86 Total Liabilities 9,879.22 8,296.25 7,579.23 5,851.96 Net Block 2,612.16 2,601.87 2,438.98 1,626.81 Gross Block 3,774.93 3,564.57 3,225.28 2,260.11 Accumulated Depreciation 1,162.77 962.70 786.30 633.30 Non Current Assets 6,508.14 5,947.57 5,400.24 3,989.17 Capital Work in Progress 533.24 416.57 405.16 121.00 Non Current Investment 1,646.88 1,646.87 1,592.52 1,591.52 Long Term Loans & Adv. 1,715.86 1,282.22 963.54 649.84 Other Non Current Assets 0.00 0.04 0.04 0.00 Current Assets 3,371.08 2,348.68 2,178.99 1,862.79 Current Investments 61.28 100.12 37.01 0.00 Inventories 1,153.04 818.61 535.51 420.88 Sundry Debtors 1,331.38 909.56 989.22 839.75 Cash & Bank 241.73 64.16 137.23 152.35 Other Current Assets 583.65 28.98 39.00 44.50 Short Term Loans & Adv. 523.41 427.25 441.02 405.31 Net Current Assets 1,063.73 397.39 523.60 295.83 Total Assets 9,879.22 8,296.25 7,579.23 5,851.96

Description Mar 24 Mar 23 Mar 22 Mar 21
Shareholder's Funds 7,911.37 6,773.50 6,696.60 5,605.00 Share Capital 1,322.95 1,193.32 1,185.91 994.60 Total Reserves 6,560.95 5,580.18 5,510.69 4,610.30 Non-Current Liabilities 2,928.77 3,812.00 2,902.58 2,560.38 Secured Loans 2,483.75 3,383.54 2,622.14 2,339.16 Unsecured Loans 0.00 0.00 0.00 0.00 Long Term Provisions 316.45 275.97 145.34 6.78 Current Liabilities 4,457.10 3,851.04 3,118.01 2,590.70 Trade Payables 1,538.37 1,192.71 1,026.35 917.94 Other Current Liabilities 1,575.68 1,305.30 1,242.76 1,140.63 Short Term Borrowings 1,171.38 1,302.29 658.76 360.52 Short Term Provisions 171.67 50.74 190.14 171.61 Total Liabilities 15,297.24 14,436.54 12,717.19 10,756.08 Net Block 7,989.93 7,468.60 6,879.18 6,105.49 Gross Block 12,137.48 10,842.12 9,510.49 8,173.25 Accumulated Depreciation 4,147.55 3,373.52 2,631.31 2,067.76 Non Current Assets 9,744.97 9,593.07 8,565.30 7,006.96 Capital Work in Progress 1,115.80 1,418.58 1,172.34 626.65 Non Current Investment 240.26 211.87 216.77 122.67 Long Term Loans & Adv. 398.98 493.98 296.97 152.11 Other Non Current Assets 0.00 0.04 0.04 0.04 Current Assets 5,552.27 4,843.47 4,151.89 3,749.12 Current Investments 144.69 427.11 50.40 0.00 Inventories 2,175.88 1,681.37 1,388.80 1,232.00 Sundry Debtors 2,134.43 1,799.34 1,785.28 1,574.94 Cash & Bank 482.56 307.56 328.99 405.62 Other Current Assets 614.71 140.24 93.66 141.01 Short Term Loans & Adv. 532.78 487.85 504.76 395.55 Net Current Assets 1,095.17 992.43 1,033.88 1,158.42 Total Assets 15,297.24 14,436.54 12,717.19 10,756.08

Cash Flow

Standalone Figures in Rs. Crores /

Consolidated

Description Mar 24 Mar 23 Mar 22 Mar 21
Cash From Operating Activity 358.29 71.52 249.19 34.72 PBT 507.62 123.69 477.41 349.11 Adjustment 221.26 50.70 42.92 8.96 Changes in Working Capital -292.78 -42.84 -168.48 -228.06 Cash after chg. in Working capital 436.10 131.55 351.85 130.01 Interest Paid 0.00 0.00 0.00 0.00 Tax Paid -77.81 -60.03 -102.66 -95.29 Other Direct Exp. Paid 0.00 0.00 0.00 0.00 Extra & Other Items 0.00 0.00 0.00 0.00 Cash From Investing Activity -635.52 -435.05 -1,245.61 -4,382.89 Net Fixed Assets -327.03 -350.70 -1,249.33 Net Investments 38.83 -117.46 -38.01 Others -347.32 33.11 41.73 Cash from Financing Activity 451.38 290.12 896.40 4,494.16 Net Cash Inflow / Outflow 174.15 -73.41 -100.02 145.99 Opening Cash & Equivalents 54.28 127.69 146.72 0.74 Closing Cash & Equivalent 228.80 54.28 127.69 146.73

Description Mar 24 Mar 23 Mar 22 Mar 21
Cash From Operating Activity 1,004.54 483.89 766.42 597.58 PBT 119.80 -160.56 441.03 639.68 Adjustment 1,275.88 1,135.53 787.10 721.99 Changes in Working Capital -234.30 -302.08 -292.29 -619.58 Cash after chg. in Working capital 1,161.38 672.89 935.84 742.09 Interest Paid 0.00 0.00 0.00 0.00 Tax Paid -156.84 -189.00 -169.42 -144.51 Other Direct Exp. Paid 0.00 0.00 0.00 0.00 Extra & Other Items 0.00 0.00 0.00 0.00 Cash From Investing Activity -434.01 -1,338.78 -1,812.10 -4,479.93 Net Fixed Assets -327.03 -350.70 -1,249.33 Net Investments 38.83 -117.46 -38.01 Others -145.81 -870.62 -524.76 Cash from Financing Activity -422.36 817.79 794.19 3,976.83 Net Cash Inflow / Outflow 148.17 -37.10 -251.49 94.48 Opening Cash & Equivalents 53.23 85.18 261.97 151.95 Closing Cash & Equivalent 219.19 53.23 85.18 261.97

Financial Ratios

Standalone /

Consolidated

Description Mar 24 Mar 23 Mar 22 Mar 21
Book Value (Rs.) 50.53 43.06 42.19 41.23 ROA 4.30% 0.88% 5.47% 9.77% ROE 6.55% 1.34% 7.97% 13.94% ROCE 8.33% 3.64% 9.86% 16.21% Fixed Asset Turnover 1.25 1.05 1.24 1.30 Receivable days 88.86 96.97 98.40 104.30 Inventory Days 78.18 69.15 51.45 52.27 Payable days 161.78 145.35 143.86 173.65 Cash Conversion Cycle 5.26 20.77 5.99 -17.08 Total Debt/Equity 0.17 0.31 0.23 0.04 Interest Cover 5.74 2.07 9.07 146.81

Description Mar 24 Mar 23 Mar 22 Mar 21
Book Value (Rs.) 59.59 55.44 55.15 56.35 ROA 0.12% -1.37% 3.20% 7.76% ROE 0.24% -2.77% 6.11% 14.90% ROCE 5.07% 1.95% 7.10% 13.06% Fixed Asset Turnover 0.82 0.80 0.83 0.77 Receivable days 76.20 80.70 83.94 91.03 Inventory Days 74.72 69.11 65.47 71.21 Payable days 168.73 149.81 144.76 162.72 Cash Conversion Cycle -17.80 0.00 4.65 -0.47 Total Debt/Equity 0.58 0.81 0.60 0.52 Interest Cover 1.40 0.65 3.45 6.81

Top Investors:

ca alchemy investments

hdfc trustee company limited-hdfc flexi cap fund

east bridge capital master fund i ltd

life insurance corporation of india

indiahold limited

llp

investor education and protection fund (iepf)

Annual Reports:

FY 2024

FY 2023

FY 2022

News Update:

Piramal Pharma reports over 4-fold jump in Q2 consolidated net profit
24th Oct 2024, 11:30 AM

Consolidated total income of the company increased by 17.46% at Rs 2302.86 crore for Q2FY25
Read More
Piramal Pharma - Quarterly Results
23rd Oct 2024, 20:07 PM

Read More
Piramal Pharma’s PPS business to invest $80 million to expand Kentucky facility
1st Oct 2024, 11:58 AM

Upon completion of the expansion in Q1 of 2027, this capacity will increase to over 240 annual batches
Read More
Piramal Pharma gets SBTi approval for GHG Commitment
17th Sep 2024, 10:57 AM

Piramal Pharma has committed to reduce absolute scope 1 and 2 GHG emissions 42% by FY2030 from a FY2022 base year
Read More
Piramal Pharma to subscribe preference shares in arm against outstanding loan
30th Aug 2024, 11:44 AM

The Administrative Committee of the Board of Directors of the Company at its meeting held on August 30, 2024, has approved the same
Read More
Piramal Pharma gets nod to sell unit in Thane
31st Jul 2024, 14:11 PM

The administrative Committee of the Board of Directors of the Company at its meeting held on July 30, 2024 has approved the same
Read More

Piramal Pharma Ltd.

Pharmaceuticals & Drugs

BSE: 543635 | NSE: PPLPHARMA

Stock Summary

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

EBITDA CAGR (%)

PAT CAGR (%)

P:E (Median)

P:BV (Average)

EV:EBITDA (Average)

Quarterly Results

Consolidated Figures in Rs. Crores /

Annual Results

Standalone Figures in Rs. Crores /

Results Balance Sheet

Standalone Figures in Rs. Crores /

Cash Flow

Standalone Figures in Rs. Crores /

Financial Ratios

Standalone /

Top Investors:

Annual Reports:

News Update:

Piramal Pharma Ltd.

Pharmaceuticals & Drugs

BSE: 543635 | NSE: PPLPHARMA

Stock Summary

Shareholding Pattern

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

EBITDA CAGR (%)

PAT CAGR (%)

P:E (Median)

P:BV (Average)

EV:EBITDA (Average)

Quarterly Results

Consolidated Figures in Rs. Crores /

Annual Results

Standalone Figures in Rs. Crores /

Results Balance Sheet

Standalone Figures in Rs. Crores /

Cash Flow

Standalone Figures in Rs. Crores /

Financial Ratios

Standalone /

Top Investors:

Annual Reports:

News Update: